Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 19/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550638 | 0.90 | CRHR1 (0.57) | CRHR1SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL5551914 | 0.89 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL5571989 | 0.89 | CRHR1 (0.51) | CRHR1SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL5569003 | 0.88 | CRHR1 (0.51) | CRHR1SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL5571467 | 0.87 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL3249256 | 0.86 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL5572320 | 0.85 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5568075 | 0.82 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5572074 | 0.82 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL5572490 | 0.81 | CRHR1 (0.46) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219232-A1 | Chemical Compounds | GLAXO GROUP LIMITED | 2007-09-20 | — | — | US | disclosed |
| US-7253284-B2 | Chemical compounds | GIAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1695974-A1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-30 | — | — | EP | disclosed |
| US-20040171607-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171607-A1 | Chemical compounds | CBR3, CBR1, CYP2B6 | CRHR1 52/4885SLC2A1 2596/4885SLC2A3 2164/4885 |
| US-20070219232-A1 | Chemical Compounds | CBR3, CBR1, HCAR3 | CRHR1 30/4885SLC2A1 2954/4885SLC2A3 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.